Cannara Biotech (USD-listed)

Compare like-for-like revenue

The annual revenue series records USD 11.67m for the period ended December 31, 2025. That is 14.6% below the same reporting basis a year earlier.

Revenue and profitability are separate

The matching annual net loss is USD 842,820. This is the reported result for 2025-12-31, not a future earnings estimate.

Put cash beside operating cash flow

Period-end cash was USD 1.48m at 2025-12-31. The matching annual operating cash outflow was USD 1.4m. Later financing and cash movements are not established by this snapshot.

What to investigate next

• Resolve the conflicting financial observations against the primary report.
• Confirm the financial-statement currency against the original report; the listing currency is different.
• Read the latest linked company disclosures and any reporting after the financial period.
• Check post-period financing, share issuance and changes in cash before drawing a current valuation conclusion.

Evidence boundaries

• Conflicting observations for the same concept, period and reporting basis are withheld.
• No dated primary company disclosures were supplied; absence in this feed is not a clean regulatory check.
• Financial-statement units differ from the listing currency. Values are kept in their reported units; valuation and cross-currency comparisons are withheld.
• The earlier rating is not presented as a current conclusion. This report is rebuilt from dated evidence.